Search Result
Results for "
nonalcoholic steatohepatitis
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
3
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-149831
-
|
|
FXR
|
Metabolic Disease
|
ZLY28 is the first-in-class intestinal restricted and orally active FXR and FABP1 dual modulator. ZLY28 also is a novel anti-NASH agent. ZLY28 can be used for the research of nonalcoholic steatohepatitis (NASH) .
|
-
-
- HY-148814
-
BI-3231
1 Publications Verification
|
17β-HSD
|
Metabolic Disease
|
|
BI 3231, a chemical probe, is a potent and selective hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) inhibitor, with IC50s of 1 and 13 nM for hHSD17B13 and mHSD17B13, respectively. BI 3231 has the potential for the research of nonalcoholic steatohepatitis (NASH) and other liver diseases .
|
-
-
- HY-156034A
-
|
NLRP3-IN-19 sodium
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
JT001 (NLRP3-IN-19) sodium is a potent, specific and orally active inhibitor of NLRP3. JT001 sodium can inhibit NLRP3 inflammasome assembly, resulting in the inhibition of cytokine release and the prevention of pyroptosis. JT001 sodium can be used for the research of nonalcoholic steatohepatitis and liver fibrosis .
|
-
-
- HY-144111
-
|
|
PPAR
|
Inflammation/Immunology
|
|
PPARα/δ agonist 1 is a potent PPARα/PPARδ dual agonist (PPARα EC50=7.0 nM; PPARδ EC50=8.4 nM). PPARα/δ agonist 1 is a high selectivity over PPARγ (PPARγ EC50=1316.1 nM). PPARα/δ agonist 1 has the potential for the research of nonalcoholic steatohepatitis .
|
-
-
- HY-149987
-
|
KHK-IN-3
|
Ketohexokinase
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
|
KHK-IN-3 (Example 1) is a ketohexokinase (KHK) inhibitor. KHK-IN-3 can be used in the study of kidney disease, nonalcoholic steatohepatitis (NASH), diabetes and heart failure. KHK is a rate-limiting enzyme and fructokinase involved in fructose metabolism. KHK catalyzes the phosphorylation of fructose to fructose-1-phosphate (FIP) at the expense of ATP. The lack of feedback inhibition of fructose metabolism triggers the accumulation of downstream intermediates such as lipogenesis, gluconeogenesis, and oxidative phosphorylation .
|
-
-
- HY-P3504
-
|
JNJ-64565111; HM12525A; MK-6024
|
GCGR
iGluR
|
Metabolic Disease
|
|
Efinopegdutide (JNJ-64565111) is a potent dual glucagon-like peptide-1 (GLP-1)/glucagon receptor (GluR) agonist, which activates both the GLP-1 and glucagon receptors. Efinopegdutide can be used in research of nonalcoholic steatohepatitis (NASH) .
|
-
-
- HY-N10640
-
|
|
FXR
|
Inflammation/Immunology
|
|
Alismanol M is a farnesoid X receptor (FXR) agonist with an EC50 value of 50.25 μM. Alismanol M is a protostane-type triterpenoid that can be isolated from the rhizome of Alisma orientale. Alismanol M can be used for the research of cholestasis and nonalcoholic steatohepatitis .
|
-
-
- HY-156034
-
|
NLRP3-IN-19
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
JT001 (NLRP3-IN-19) is a potent, specific and orally active inhibitor of NLRP3. JT001 can inhibit NLRP3 inflammasome assembly, resulting in the inhibition of cytokine release and the prevention of pyroptosis. JT001 can be used for the research of nonalcoholic steatohepatitis and liver fibrosis .
|
-
-
- HY-P6177
-
|
|
Dipeptidyl Peptidase
|
Inflammation/Immunology
|
|
SGP8 (IAVPGEVA) is an octapeptide produced by hydrolysis of soybean 11S globulin, which has the effects of regulating lipid metabolism, inflammation and fibrosis. SGP8 (IAVPGEVA) exhibits inhibitory activity against DPP4 and inhibits the JNK-c-Jun signaling pathway, and has the ability to inhibit non-alcoholic steatohepatitis (NASH) .
|
-
-
- HY-172134
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
NLRP3-IN-70 (Compound 5m) is an NLRP3 inflammasome inhibitor with low oral bioavailability. NLRP3-IN-70 can directly bind to the NACHT domain of the NLRP3 protein and block the interaction of NLRP3 and ASC, thus inhibiting ASC oligomerization and NLRP3 inflammasome assembly. NLRP3-IN-70 can be used in the research of sepsis and nonalcoholic steatohepatitis .
|
-
-
- HY-139562
-
|
|
FXR
|
Metabolic Disease
|
|
BMS-986318 is a potent nonbile acid FXR agonist with EC50s of 53 and 350 nM in the FXR Gal4 and SRC-1 recruitment assays, respectively. BMS-986318 has a suitable ADME profile, and demonstrates efficacy in the mouse bile duct ligation model of liver cholestasis and fibrosis.BMS-986318 can be used for the research of nonalcoholic steatohepatitis .
|
-
-
- HY-147195
-
-
-
- HY-149218
-
|
|
Thyroid Hormone Receptor
|
Metabolic Disease
Inflammation/Immunology
|
|
THR-β agonist 6 is an orally active, selective thyroid hormone receptor β (THR-β) agonist with EC50s of 0.03 μM and 0.22 μM for THR-β and THR-α, respectively. THR-β agonist 6 exhibits an xcellent liver-to-serum ratio of 93:1 in mice. THR-β agonist 6 has the potential for nonalcoholic steatohepatitis (NASH) research .
|
-
-
- HY-109096
-
|
LMB763
|
FXR
Autophagy
|
Inflammation/Immunology
|
|
Nidufexor (LMB763) is an orally-available farnesoid X receptor (FXR) agonist for the research of nonalcoholic steatohepatitis (NASH) .
|
-
-
- HY-119039
-
RU-301
1 Publications Verification
|
TAM Receptor
|
Inflammation/Immunology
Cancer
|
|
RU-301 is a pan TAM inhibitor that blocks Gas6-induced TAM activation and tumorigenicity. RU-301 significantly reduces nonalcoholic steatohepatitis (NASH) fibrosis, along with attenuates ERK activation and TGFβ1 expression. RU-301 can be used in studies of cancer and nonalcoholic steatohepatitis .
|
-
-
- HY-163886
-
|
|
Ketohexokinase
|
Metabolic Disease
|
|
KHK-IN-5 (Compound 18) is a KHK inhibitor. KHK-IN-5 can be used for the research of nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and type 2 diabetes (T2DM) .
|
-
-
- HY-16521
-
|
|
Caspase
|
Inflammation/Immunology
|
|
VX-166, a pan caspase inhibitor, can be used for the research of Non- Alcoholic Fatty Liver Disease (NAFLD), nonalcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), and other diseases involving fibrosis, steatosis, or inflammation of the liver .
|
-
-
- HY-163071
-
|
|
FXR
|
Metabolic Disease
|
|
V023-9340 is a potent FXR inhibitor with IC50 of 4.27 μM that can be used in NASH (nonalcoholic steatohepatitis) research .
|
-
-
- HY-109002
-
-
-
- HY-153114
-
|
|
FXR
|
Inflammation/Immunology
|
|
HEC96719 is a selective and orally active tricyclic farnesoid X receptor (FXR) agonist with EC50 values of 1.37 and 1.55 nM by time-resolved fluorescence energy transfer (TR-FRET) and luciferase reporter assays, respectively. HEC96719 significantly improves non-alcoholic steatohepatitis (NASH) and liver fibrosis with favorable tissue distribution in liver and intestine. HEC96719 can be used for the research of non-alcoholic steatohepatitis .
|
-
-
- HY-P11042
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
TE-8105 is a GLP-1 receptor agonist that has demonstrated prolonged and potent efficacy in models of diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
|
-
-
- HY-170571
-
|
|
Mitochondrial Metabolism
|
Metabolic Disease
Inflammation/Immunology
|
|
BE2647 is a selective inhibitor for mitochondrial pyruvate carrier (MPC) with an EC50 of 70 nM. BE2647 exhibits good metabolic stability in mouse liver microsomes. BE2647 can be used in research of metabolic diseases, non-alcoholic fatty liver disease (MASLD), or non-alcoholic steatohepatitis (MASH) .
|
-
-
- HY-161979
-
|
|
17β-HSD
|
Cancer
|
|
HSD17B13-IN-103 (Compound 44) is a HSD17B13 inhibitor. HSD17B13-IN-103 can be used in the study of non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) .
|
-
-
- HY-137922
-
|
|
Mitochondrial Metabolism
|
Metabolic Disease
|
|
SHS4121705 is an orally effective mitochondrial uncoupling agent with an IC50 of 4.3 μM in L6 myoblasts. SHS4121705 can be used in the study of non-alcoholic steatohepatitis (NASH) .
|
-
-
- HY-113111
-
|
|
Endogenous Metabolite
|
Inflammation/Immunology
|
|
11,12-DiHETrE, an endogenous metabolite, is a Cytochrome P450 (P450) eicosanoid. 11,12-DiHETrE can be used for preterm labor research. 11,12-DiHETrE can be used as a single biomarker for differentiating NAFL (nonalcoholic fatty liver) from NASH (nonalcoholic steatohepatitis) .
|
-
-
- HY-116374A
-
|
Lithocholylglycine sodium
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Glycolithocholic acid (Lithocholylglycine) sodium is the sodium salt of Glycolithocholic acid. Glycolithocholic acid is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .
|
-
-
- HY-101190
-
-
-
- HY-153476A
-
|
|
Insulin Receptor
GLP Receptor
|
Metabolic Disease
|
|
GIP/GLP-1 dual receptor agonist-1 (Compound 4) (sodium) is a GIP/GLP-1 receptor agonist. GIP/GLP-1 dual receptor agonist-1 (sodium) can be used in the research of metabolic disorders and fatty liver diseases, including nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD).
|
-
-
- HY-116374
-
|
Lithocholylglycine
|
Endogenous Metabolite
|
Inflammation/Immunology
|
|
Glycolithocholic acid (Lithocholylglycine), an endogenous metabolite, is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .
|
-
-
- HY-153476
-
|
|
GCGR
|
Metabolic Disease
|
|
GIP/GLP-1 dual receptor agonist-1 (compound 4) is a GIP/GLP-1 receptor agonist. GIP/GLP-1 dual receptor agonist-1 can be used in the research of metabolic disorders and fatty liver diseases, including nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) .
|
-
-
- HY-167643
-
|
|
Drug Metabolite
|
Metabolic Disease
Inflammation/Immunology
|
|
Hydroxy tipelukast (Compound MN-002), the metabolite of Compound MN-001, is an orally active phenoxyalkylcarboxylic acid. Hydroxy tipelukast inhibits liver steatosis, lobular inflammation, hepatic ballooning, and hepatic scarring, and reduces liver hydroxyproline levels. Hydroxy tipelukast is promising for research of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) .
|
-
-
- HY-19796
-
|
Aramchol; C20-FABAC
|
Stearoyl-CoA Desaturase (SCD)
|
Metabolic Disease
|
|
Icomidocholic acid (Aramchol) is a lipid molecule synthesized from cholic acid and arachidic acid. Icomidocholic acid is an orally active SCD1 inhibitor and cholesterol solubilizer with antifibrotic effects. Icomidocholic acid can reduce liver fat content, dissolve cholesterol crystals and prevent gallstone formation. Icomidocholic acid can be used in the study of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) .
|
-
-
- HY-12216
-
Resmetirom
Maximum Cited Publications
12 Publications Verification
MGL-3196; VIA-3196
|
Thyroid Hormone Receptor
|
Cardiovascular Disease
Endocrinology
|
|
Resmetirom (MGL-3196) is a highly selective and orally active thyroid hormone receptor β (THR-β) agonist with an EC50 value of 0.21 μM. Resmetirom can be used for the study of noncirrhotic nonalcoholic steatohepatitis .
|
-
-
- HY-170516
-
-
-
- HY-147622
-
|
|
GCGR
|
Metabolic Disease
|
|
GLP-1R agonist 9 (Compound 96) is a GLP-1R agonist with EC50 values of 1.1 nM and 11 nM against CHO GLP-1R Clone H6 and CHO GLP-1R Clone C6, respectively .
|
-
-
- HY-149893
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
MGAT2-IN-4 (compound 33) is an inhibitor of monoacylglycerol transferase 2 (MGAT2), with liver metabolic stability. MGAT2-IN-4 can be used for research on obesity, diabetes and non-alcoholic steatohepatitis (NASH) .
|
-
-
- HY-145632
-
|
ALT-801
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
Pemvidutide (ALT-801) is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide can be used in non-alcoholic steatohepatitis (NASH) and obesity research .
|
-
-
- HY-148926
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-1 (compound 2) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-1? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .
|
-
-
- HY-161226
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-42 (compound 10)? is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-42? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .
|
-
-
- HY-163247
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-35 (compound 76) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-35? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .
|
-
-
- HY-163242
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-28 (compound? 47) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-28? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .
|
-
-
- HY-161225
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-40 (compound 6) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-40? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .
|
-
-
- HY-163244
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-30 (compound 64) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-30? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .
|
-
-
- HY-157663
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-36 (compound 116) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-36? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .
|
-
-
- HY-173565
-
|
|
Acetyl-CoA Carboxylase
|
Inflammation/Immunology
|
|
ACC-IN-1 (Compound B1) is an allosteric inhibitor of acetyl-CoA carboxylase (ACC). ACC-IN-1 targets ACC to regulate lipid metabolism, which can improve liver steatosis, inflammation related to non-alcoholic steatohepatitis (NASH) .
|
-
-
- HY-125953
-
|
Ceramide (Egg, Chicken)
|
Reactive Oxygen Species (ROS)
Apoptosis
|
Metabolic Disease
|
|
Ceramide (Egg) is an intermediate of lipid. Ceramide (Egg) can be synthesized either by de novo biosynthesis or by salvage. Ceramide (Egg) level is associated with inflammation, ROS production and apoptosis. Ceramide (Egg) can be studied in research on non-alcoholic steatohepatitis (NASH) pathogenesis .
|
-
-
- HY-109083
-
|
GS-9674
|
FXR
Autophagy
|
Inflammation/Immunology
|
|
Cilofexor (GS-9674) is a potent, selective and orally active nonsteroidal FXR agonist with an EC50 of 43 nM. Cilofexor has anti-inflammatory and antifibrotic effects. Cilofexor has the potential for primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH) research .
|
-
-
- HY-W044764R
-
|
|
Carboxypeptidase
|
Neurological Disease
Metabolic Disease
|
|
2-Benzylsuccinic acid (DL-Benzylsuccinic acid) is an orally active carboxypeptidase A and Nna1 inhibitor. 2-Benzylsuccinic acid reduces cold hyperalgesia. 2-Benzylsuccinic acid can be used for the researches of neuropathic pain, non-alcoholic steatohepatitis .
|
-
-
- HY-W044764
-
|
DL-Benzylsuccinic acid
|
Carboxypeptidase
|
Neurological Disease
Metabolic Disease
|
|
2-Benzylsuccinic acid (DL-Benzylsuccinic acid) is an orally active carboxypeptidase A and Nna1 inhibitor. 2-Benzylsuccinic acid reduces cold hyperalgesia. 2-Benzylsuccinic acid can be used for the researches of neuropathic pain, non-alcoholic steatohepatitis .
|
-
-
- HY-116374S
-
-
- HY-145632A
-
|
ALT-801 TFA
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
Pemvidutide (ALT-801) TFA is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide TFA can be used in non-alcoholic steatohepatitis (NASH) and obesity research .
|
-
- HY-146997
-
|
|
Thyroid Hormone Receptor
|
Metabolic Disease
|
|
TRβ agonist 1 is a selective and mutation-sensitive thyroid hormone receptor β (TRβ) agonist, with an EC50 value of 21 nM. TRβ agonist 1 can be used for researching dyslipidemia, nonalcoholic steatohepatitis (NASH), and resistance to thyroid hormone (RTH) .
|
-
- HY-162223
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-97 (compound 4) is a potent hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) inhibitor with an IC50 value of ≤0.1 µM. HSD17B13-IN-97 has the potential for the research of Nonalcoholic fatty liver diseases (NAFLDs), nonalcoholic steatohepatitis (NASH) or or drug induced liver injury (DILI) .
|
-
- HY-156065
-
|
|
Keap1-Nrf2
|
Metabolic Disease
|
|
S217879 is a highly potent and selective NRF2 activator. S217879 disrupts the KEAP1-NRF2 interaction leading to robust NRF2 pathway activation. S217879 can be used for non-alcoholic steatohepatitis (NASH) research .
|
-
- HY-143613A
-
|
|
Thyroid Hormone Receptor
|
Metabolic Disease
|
|
THR-β agonist 2 diacetate (Compound 3) is a potent agonist of THR-β. THR-β agonist 2 diacetate has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases .
|
-
- HY-161218
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-17 (compound 9) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of ＜ 0.1 μM and? ＜ 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-17? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .
|
-
- HY-161223
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-27 (compound 30) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of ＜ 0.1 μM and ?＜ 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-27? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .
|
-
- HY-161220
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-19 (compound 16) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of ＜ 0.1 μM and? ＜ 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-19? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .
|
-
- HY-161224
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-31 (compound 32) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of ＜ 0.1 μM and? ＜ 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-31? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .
|
-
- HY-161217
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-16 (compound 8) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of ＜ 0.1 μM and? ＜ 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-16? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .
|
-
- HY-161221
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-21 (compound 17) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of ＜ 0.1 μM and? ＜ 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-21? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .
|
-
- HY-161222
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-23 (compound 18) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of ＜ 0.1 μM and? ＜ 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-23? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .
|
-
- HY-161219
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-18 (compound 13) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of ＜ 0.1 μM and? ＜ 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-18? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .
|
-
- HY-116374R
-
|
Lithocholylglycine (Standard)
|
Endogenous Metabolite
|
Inflammation/Immunology
|
|
Glycolithocholic acid (Standard) is the analytical standard of Glycolithocholic acid. This product is intended for research and analytical applications. Glycolithocholic acid (Lithocholylglycine), an endogenous metabolite, is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .
|
-
- HY-P99930
-
|
|
FGFR
|
Metabolic Disease
|
|
Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis .
|
-
- HY-P99697
-
|
PRO 140
|
CCR
HIV
|
Infection
Cancer
|
|
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer .
|
-
- HY-168327
-
|
|
FXR
|
Inflammation/Immunology
|
|
LH10 is a fexaramine-based agonist for FXR with an EC50 of 0.14 μM. LH10 exhibits liver protection efficacy, ameliorates the alpha naphthylisothiocyanate (ANIT)-induced cholestasis, APAP (HY-66005)-induced acute liver injury and non-alcoholic steatohepatitis (NASH) in mouse models .
|
-
- HY-108022
-
-
- HY-150787
-
|
|
FXR
Cytochrome P450
|
Metabolic Disease
|
|
BMS-986339 is an orally active, potent FXR agonist. BMS-986339 forms H-bond with His298 and ASN287 residues. BMS-986339 can be used in the research of primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH), anti-fibrosis .
|
-
- HY-173497
-
-
- HY-147246
-
|
HTD1801; BUDCA
|
Biochemical Assay Reagents
|
Metabolic Disease
|
|
Berberine ursodeoxycholate (HTD1801), an ionic salt of Berberine and Ursodeoxycholic acid, is an orally active and potent hypolipidemic agent. Berberine ursodeoxycholate shows significantly great reduction in liver fat content. Berberine ursodeoxycholate has a broad spectrum of metabolic activity. Berberine ursodeoxycholate can be used for the research of hyperlipidemia, non-alcoholic steatohepatitis (NASH) and diabetes .
|
-
- HY-174253
-
|
|
17β-HSD
|
Metabolic Disease
|
|
HSD17B13-IN-105 (Compound EX.87) is a selective 17β-hydroxysteroid dehydrogenase 13 (17BHSD13) inhibitor with an IC50 value of 0.036 μM, showing high selectivity over 17BHSD4 (with an IC50 value of 31.5 μM). HSD17B13-IN-105 is promising for research of liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) .
|
-
- HY-143614
-
|
|
Thyroid Hormone Receptor
|
Metabolic Disease
|
|
THR-β agonist 3 is a potent agonist of THR-β. THR-β agonist 3 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021129827A1, compound 6) .
|
-
- HY-W750488
-
|
Lithocholylglycine-d5
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Inflammation/Immunology
|
|
Glycolithocholic acid-d5 (Lithocholylglycine-d5) is the deuterium labeled Glycolithocholic acid (HY-116374). Glycolithocholic acid (Lithocholylglycine), an endogenous metabolite, is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .
|
-
- HY-156121
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
Cancer
|
|
NLRP3-IN-20 (compound 11) is an orally available inhibitor of the NLRP3 inflammasome with an IC50 of 25 nM for IL-1β secretion. NLRP3-IN-20 has excellent pharmacokinetic properties and demonstrated significant efficacy in models of non-alcoholic steatohepatitis, fatal septic shock, and colitis .
|
-
- HY-143613
-
|
|
Thyroid Hormone Receptor
|
Metabolic Disease
|
|
THR-β agonist 2 is a potent agonist of THR-β. THR-β agonist 2 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021121210A1, compound 3) .
|
-
- HY-P3463
-
|
GLP-1 (human)
|
GCGR
|
Metabolic Disease
Inflammation/Immunology
|
|
Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH) .
|
-
- HY-169792
-
|
|
FXR
Aminotransferases (Transaminases)
|
Metabolic Disease
Inflammation/Immunology
|
|
HPG1860 is an orally active, highly selective and potent FXR agonist, with an EC50 of 18 nM (FXR-luciferase reporter assay). HPG1860 has EC50 values >30.0 μM for TGR5 and 13 other related nuclear receptors (cAMP biological assay). HPG1860 can be used for the research of non-alcoholic steatohepatitis (NASH) .
|
-
- HY-142917
-
|
|
Thyroid Hormone Receptor
|
Metabolic Disease
|
|
THR-β agonist 4 is a potent agonist of THR-β. THR-β agonist 4 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021143706A1, compound 72) .
|
-
- HY-103479
-
|
|
Acyltransferase
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Cancer
|
|
GOAT-IN-1 is an inhibitor of ghrelin O-acyltransferase (GOAT), which could be useful for the prophylaxis or treatment of obesity, diabetes, hyperlipidemia, metabolic, non-alcoholic fatty liver, steatohepatitis, sarcopenia, appetite control, alcohol/narcotic dependence, Alzheimer’s disease, Parkinson’s disease, cerebrovascular dementia, cerebral apoplexy, cerebral infarction, cardic disease, some kind of tumors.
|
-
- HY-159595
-
|
|
LDLR
PCSK9
|
Metabolic Disease
Inflammation/Immunology
|
PCSK9-IN-29 is a lipid-lowering agent. PCSK9-IN-29 can increase low-density lipoprotein receptor (LDLR) protein expression and decrease PCSK9 protein expression in hepG2 cells. PCSK9-IN-29 can reduce the levels of serum LDL-C, TC, and liver enzyme ALT in crab eating macaques fed a high-fat diet, lower body weight and fat, and increase bone mineral content. PCSK9-IN-29 can be used for research on non-alcoholic fatty liver disease and obesity .
|
-
- HY-135644
-
|
CRV431
|
Cyclophilin
Sirtuin
Nuclear Factor of activated T Cells (NFAT)
Interleukin Related
|
Cancer
|
|
Rencofilstat (CRV431) is an orally active pan-cyclophilin inhibitor with IC50 values of 2.5 nM, 3.1 nM, 2.8 nM, 7.3 nM for Cyp A, CypB, Cyp D and Cyp G, respectively. Rencofilstat reduces fibrosis and tumor growth in models of chronic liver disease. Rencofilstat can be used for the study of nonalcoholic steatohepatitis (NASH), hepatocellular carcinoma and viral hepatitis-induced liver disease .
|
-
- HY-134988
-
|
|
FXR
Phosphatase
Cytochrome P450
|
Inflammation/Immunology
|
|
EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC50 values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells). EDP-305 shows a potent and consistent antifibrotic effect. EDP-305 can be used for primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) research .
|
-
- HY-151481
-
|
|
FXR
|
Metabolic Disease
|
|
FXR antagonist 1 (compound F6) is an orally active and selective intestinal FXR antagonist (IC50=2.1 μM). FXR antagonist 1 selectively inhibits intestinal FXR signalling through antagonism of intestinal FXR and feedback activation of hepatic FXR to improve hepatic steatosis, inflammation and fibrosis in NASH (nonalcoholic steatohepatitis) models. FXR antagonist 1 can be used in NASH studies .
|
-
- HY-155525
-
|
|
PPAR
|
Metabolic Disease
Inflammation/Immunology
|
|
Anti-NASH agent 1 (compound 3d)，a derivative of Elafibranor (HY-16737)，is a potent agonist of PPAR-α/δ，targeting to nonalcoholic steatohepatitis (NASH). Anti-NASH agent 1 (3-10 mg/kg; 4 weeks) improves hyperlipidemia，liver fat degeneration and liver inflammation in Methionine-choline deficiency (MCD) induced NASH mice model. Anti-NASH agent 1 shows low liver toxicity and potent liver protection effect .
|
-
- HY-146729
-
|
|
ASK1
MAP3K
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
ASK1-IN-3 is a potent and selective ASK1 kinase inhibitor with IC50 of 33.8 nM, as well as inhibits several cell cycle regulating kinases. ASK1-IN-3 has strong HepG2 cancer cells apoptosis induction and potent cell cycle arrest activities .
|
-
- HY-115319
-
|
|
Ferroptosis
|
Inflammation/Immunology
|
|
CP-24879 (hydrochloride) is a potent, selective and combined delta5D/delta6D inhibitor. CP-24879 (hydrochloride) can significantly reduce intracellular lipid accumulation and inflammatory injury in hepatocytes. CP-24879 (hydrochloride) exhibits superior antisteatotic and anti-inflammatory actions in fat-1 and ω-3-treated hepatocytes, and can be used for non-alcoholic steatohepatitis research .
|
-
- HY-B1245
-
|
Salicylsalicylic acid; Disalicylic acid
|
Reactive Oxygen Species (ROS)
|
Inflammation/Immunology
Cancer
|
|
Salsalate is a potent antirheumatic drug with oral activity that reduces irritation during gastric absorption and avoids direct inhibition of cyclooxygenase. Salsalate not only has significant anti-inflammatory effects, but also reduces blood sugar levels, improves insulin resistance, and reduces the expression of cytokines. Salsalate can protect mice from metabolic disorders caused by high-fat diet and effectively improve the symptoms of type 2 diabetes, atherosclerosis and non-alcoholic steatohepatitis [2 ] .
|
-
- HY-N16066
-
|
CHNQD-0803
|
AMPK
Apoptosis
NF-κB
TNF Receptor
|
Inflammation/Immunology
|
|
Candidusin A (CHNQD-0803) (Compound 4) is a AMPK activator with a KD of 47.28 nM. Candidusin A can be isolated from marine fungus Aspergillus candidus. Candidusin A has cytotoxic activity and induces apoptosis in human prostate cancer cells (22Rv1, PC-3 and LNCaP cells). Candidusin A reduces adipogenesis genes expression and fat deposition, negatively regulates the NF-κB-TNFα inflammatory axis to suppress inflammation, and ameliorates liver injury and fibrosis. Candidusin A can be used for non-alcoholic steatohepatitis (NASH) research .
|
-
- HY-173443
-
-
- HY-P99143
-
|
|
Neurokinin Receptor
NF-κB
STAT
|
Inflammation/Immunology
|
|
Anti-Mouse NK1.1 Antibody (PK136) is an anti-mouse NK1.1 IgG2a monoclonal antibody. Anti-Mouse NK1.1 Antibody (PK136) can deplete natural killer (NK) cells. Anti-Mouse NK1.1 Antibody (PK136) inhibits the JAK-STAT and NF-κB signaling pathways. Anti-Mouse NK1.1 Antibody (PK136) can be used for research on inflammation conditions such as non-alcoholic steatohepatitis (NASH) .
|
-
- HY-19522C
-
|
MBX-8025 Lysine dihydrate; RWJ-800025 Lysine dihydrate
|
PPAR
|
Metabolic Disease
|
|
Seladelpar (MBX-8025) Lysine dihydrate is the Lysine dihydrate salt form of Seladelpar (HY-19522). Seladelpar Lysine dihydrate is an orally active agonist for potent PPAR-δ, with EC50 of 2 nM. Seladelpar Lysine dihydrate shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar Lysine dihydrate can be used for the study of primary biliary cholangitis. Seladelpar Lysine dihydrate normalizes hyperglycemia, hyperinsulinemia, glucose, serum lipids and cholesterol levels, ameliorates the nonalcoholic steatohepatitis in mouse model .
|
-
- HY-100008
-
|
NIK333
|
RAR/RXR
SphK
Autophagy
HCV
|
Infection
Cancer
|
|
Peretinoin is an oral acyclic retinoid with a vitamin A-like structure that targets retinoid nuclear receptors such as retinoid X receptor (RXR) and retinoic acid receptor (RAR). Peretinoin reduces the mRNA level of sphingosine kinase 1 (SPHK1) in vitro by downregulating a transcription factor, Sp1 . Peretinoin prevents the progression of non-alcoholic steatohepatitis (NASH) and the development of hepatocellular carcinoma (HCC) through activating the autophagy pathway by increased Atg16L1 expression . Peretinoin inhibits HCV RNA amplification and virus release by altering lipid metabolism with a EC50 of 9 μM .
|
-
- HY-176770
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
GLP-1R agonist 34 (Compound 1) is an orally active small molecule glucagon-like peptide-1 receptor (GLP-1R) agonist. GLP-1R agonist 34 promotes insulin secretion, inhibits glucagon release, and delays gastric emptying, thereby effectively lowering blood glucose levels. GLP-1R agonist 34 is promising for research of metabolic diseases, including type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
|
-
- HY-171850
-
|
|
GLP Receptor
|
Metabolic Disease
Inflammation/Immunology
|
|
GLP-1R modulator-1 (Compound 384) is an orally active, potent selective glucagon-like peptide-1 receptor (GLP-1R) agonist. GLP-1R modulator-1 activates G-protein coupled signaling, elevates intracellular cAMP levels, promotes insulin secretion, delays gastric emptying and suppresses appetite. GLP-1R modulator-1 is promising for research of type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
|
-
- HY-175082
-
-
- HY-P10302
-
|
|
GLP Receptor
Insulin Receptor
|
Metabolic Disease
|
|
GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
|
-
- HY-W011121
-
|
2-OG
|
GPR119
NF-κB
TGF-beta/Smad
GLP Receptor
|
Metabolic Disease
|
|
2-Oleoylglycerol (2-OG) is a lipid found in the diet. It is a GPR119 agonist, with an EC50 value of 2.5 μM in activating hGPR119 in transiently transfected COS-7 cells. 2-Oleoylglycerol enhances the inflammatory response of macrophages and promotes fibrosis by activating the GPR119/TAK1/NF-κB/TGF-β1 signaling pathway. It also stimulates glucagon-like peptide 1 (GLP-1) secretion in vivo. 2-Oleoylglycerol is expected to be used in the research of non-alcoholic steatohepatitis (NASH) .
|
-
- HY-P10337
-
|
|
GCGR
GLP Receptor
|
Metabolic Disease
Endocrinology
|
|
OXM-7 is a dual agonist of GLP-1R (EC50=0.024 nM) and GCGR (EC50=0.082 nM). OXM-7 can enhance glucose-stimulated insulin secretion and hepatic glucose output. OXM-7 lowers blood glucose levels. OXM-7 improves lipid metabolism .
|
-
- HY-100008R
-
|
NIK333 (Standard)
|
Reference Standards
RAR/RXR
SphK
Autophagy
HCV
|
Infection
Cancer
|
|
Peretinoin (Standard) is the analytical standard of Peretinoin. This product is intended for research and analytical applications. Peretinoin is an oral acyclic retinoid with a vitamin A-like structure that targets retinoid nuclear receptors such as retinoid X receptor (RXR) and retinoic acid receptor (RAR). Peretinoin reduces the mRNA level of sphingosine kinase 1 (SPHK1) in vitro by downregulating a transcription factor, Sp1[1]. Peretinoin prevents the progression of non-alcoholic steatohepatitis (NASH) and the development of hepatocellular carcinoma (HCC) through activating the autophagy pathway by increased Atg16L1 expression[2]. Peretinoin inhibits HCV RNA amplification and virus release by altering lipid metabolism with a EC50 of 9 μM[3].
|
-
- HY-N7864
-
|
all-cis-4,7,10,13,16-Docosapentaenoic acid
|
Biochemical Assay Reagents
|
Others
|
|
Docosapentaenoic acid (DPA) is a 22-carbon fatty acid found in fish oil. It is a minor component of total serum unsaturated fatty acids in humans, ranging from 0.1% to 1%, and increasing with dietary supplementation. all-cis-4,7,10,13,16-DPA, also known as Austrian acid, is an isomer of DPA. It is an omega-6 fatty acid formed by the extension and desaturation of arachidonic acid. During fatty acid desaturase syndrome, levels of this fatty acid may be reduced, which may affect development. Upregulated hepatic elongate expression of very long fatty acid protein 6 and elevated levels of very long chain fatty acids, including all-cis 4,7,10,13,16-DPA, are characteristic of nonalcoholic steatohepatitis, a precancerous disease of hepatocellular carcinoma.
|
-
- HY-W701772
-
|
2-OG-d5
|
Isotope-Labeled Compounds
GPR119
TGF-beta/Smad
NF-κB
GLP Receptor
|
Metabolic Disease
|
|
2-Oleoylglycerol-d5 (2-OG-d5) is the deuterium labeled 2-Oleoylglycerol (HY-W011121). 2-Oleoylglycerol (2-OG) is a lipid found in the diet. It is a GPR119 agonist, with an EC50 value of 2.5 μM in activating hGPR119 in transiently transfected COS-7 cells. 2-Oleoylglycerol enhances the inflammatory response of macrophages and promotes fibrosis by activating the GPR119/TAK1/NF-κB/TGF-β1 signaling pathway. It also stimulates glucagon-like peptide 1 (GLP-1) secretion in vivo. 2-Oleoylglycerol is expected to be used in the research of non-alcoholic steatohepatitis (NASH) .
|
-
- HY-P10302A
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
GLP-1R/GIPR agonist-1 soduim is the sodium salt form of GLP-1R/GIPR agonist-1 (HY-P10302). GLP-1R/GIPR agonist-1 soduim is a dual agonist for glucagon-like peptide-1 receptor (GLP-1R, EC50 is 0.57 nM) and glucose-dependent insulin releasing peptide receptor (GIPR, EC50 is 0.75 nM). GLP-1R/GIPR agonist-1 soduim lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 soduim can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
|
-
-
-
HY-L199
-
|
|
3,969 compounds
|
|
Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is the primary liver manifestation of metabolic syndrome. The growth of NAFLD has coincided with the obesity epidemic. NAFLD is composed of excess lipid accumulation in the liver, causing steatotoxicity, and shows a wide range of histopathological abnormalities. NAFLD may progress from simple steatosis to Non-alcoholic steatohepatitis (NASH) with or without fibrosis (NASH), and eventually to cirrhosis and hepatocellular carcinoma. To date, very few drugs have been approved for marketing specifically for the treatment of NAFLD, so increased efforts to develop NAFLD drugs are necessary.
MCE designs a unique collection of 3,969 small molecules with definite or potential anti-NAFLD activity, which is an important tool for studying the pathological mechanism of NAFLD and developing drugs for NAFLD.
|
| Cat. No. |
Product Name |
Type |
-
- HY-N7864
-
|
all-cis-4,7,10,13,16-Docosapentaenoic acid
|
Cell Assay Reagents
|
|
Docosapentaenoic acid (DPA) is a 22-carbon fatty acid found in fish oil. It is a minor component of total serum unsaturated fatty acids in humans, ranging from 0.1% to 1%, and increasing with dietary supplementation. all-cis-4,7,10,13,16-DPA, also known as Austrian acid, is an isomer of DPA. It is an omega-6 fatty acid formed by the extension and desaturation of arachidonic acid. During fatty acid desaturase syndrome, levels of this fatty acid may be reduced, which may affect development. Upregulated hepatic elongate expression of very long fatty acid protein 6 and elevated levels of very long chain fatty acids, including all-cis 4,7,10,13,16-DPA, are characteristic of nonalcoholic steatohepatitis, a precancerous disease of hepatocellular carcinoma.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-145632A
-
|
ALT-801 TFA
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
Pemvidutide (ALT-801) TFA is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide TFA can be used in non-alcoholic steatohepatitis (NASH) and obesity research .
|
-
- HY-P3463
-
|
GLP-1 (human)
|
GCGR
|
Metabolic Disease
Inflammation/Immunology
|
|
Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH) .
|
-
- HY-P10302A
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
GLP-1R/GIPR agonist-1 soduim is the sodium salt form of GLP-1R/GIPR agonist-1 (HY-P10302). GLP-1R/GIPR agonist-1 soduim is a dual agonist for glucagon-like peptide-1 receptor (GLP-1R, EC50 is 0.57 nM) and glucose-dependent insulin releasing peptide receptor (GIPR, EC50 is 0.75 nM). GLP-1R/GIPR agonist-1 soduim lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 soduim can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
|
-
- HY-P6177
-
|
|
Dipeptidyl Peptidase
|
Inflammation/Immunology
|
|
SGP8 (IAVPGEVA) is an octapeptide produced by hydrolysis of soybean 11S globulin, which has the effects of regulating lipid metabolism, inflammation and fibrosis. SGP8 (IAVPGEVA) exhibits inhibitory activity against DPP4 and inhibits the JNK-c-Jun signaling pathway, and has the ability to inhibit non-alcoholic steatohepatitis (NASH) .
|
-
- HY-P11042
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
TE-8105 is a GLP-1 receptor agonist that has demonstrated prolonged and potent efficacy in models of diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
|
-
- HY-153476A
-
|
|
Insulin Receptor
GLP Receptor
|
Metabolic Disease
|
|
GIP/GLP-1 dual receptor agonist-1 (Compound 4) (sodium) is a GIP/GLP-1 receptor agonist. GIP/GLP-1 dual receptor agonist-1 (sodium) can be used in the research of metabolic disorders and fatty liver diseases, including nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD).
|
-
- HY-153476
-
|
|
GCGR
|
Metabolic Disease
|
|
GIP/GLP-1 dual receptor agonist-1 (compound 4) is a GIP/GLP-1 receptor agonist. GIP/GLP-1 dual receptor agonist-1 can be used in the research of metabolic disorders and fatty liver diseases, including nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) .
|
-
- HY-145632
-
|
ALT-801
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
Pemvidutide (ALT-801) is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide can be used in non-alcoholic steatohepatitis (NASH) and obesity research .
|
-
- HY-P10302
-
|
|
GLP Receptor
Insulin Receptor
|
Metabolic Disease
|
|
GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
|
-
- HY-P10337
-
|
|
GCGR
GLP Receptor
|
Metabolic Disease
Endocrinology
|
|
OXM-7 is a dual agonist of GLP-1R (EC50=0.024 nM) and GCGR (EC50=0.082 nM). OXM-7 can enhance glucose-stimulated insulin secretion and hepatic glucose output. OXM-7 lowers blood glucose levels. OXM-7 improves lipid metabolism .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99428
-
|
NGM282
|
Inhibitory Antibodies
|
Metabolic Disease
|
|
Aldafermin (NGM282) is an analog of fibroblast growth factor 19. Aldafermin can be used for the research of nonalcoholic steatohepatitis (NASH) .
|
-
- HY-P99930
-
|
|
FGFR
|
Metabolic Disease
|
|
Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis .
|
-
- HY-P99697
-
|
PRO 140
|
CCR
HIV
|
Infection
Cancer
|
|
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer .
|
-
- HY-P99143
-
|
|
Neurokinin Receptor
NF-κB
STAT
|
Inflammation/Immunology
|
|
Anti-Mouse NK1.1 Antibody (PK136) is an anti-mouse NK1.1 IgG2a monoclonal antibody. Anti-Mouse NK1.1 Antibody (PK136) can deplete natural killer (NK) cells. Anti-Mouse NK1.1 Antibody (PK136) inhibits the JAK-STAT and NF-κB signaling pathways. Anti-Mouse NK1.1 Antibody (PK136) can be used for research on inflammation conditions such as non-alcoholic steatohepatitis (NASH) .
|
-
- HY-P3504
-
|
JNJ-64565111; HM12525A; MK-6024
|
GCGR
iGluR
|
Metabolic Disease
|
|
Efinopegdutide (JNJ-64565111) is a potent dual glucagon-like peptide-1 (GLP-1)/glucagon receptor (GluR) agonist, which activates both the GLP-1 and glucagon receptors. Efinopegdutide can be used in research of nonalcoholic steatohepatitis (NASH) .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-116374S
-
|
|
|
Glycolithocholic acid-d4 is the deuterium labeled Glycolithocholic acid. Glycolithocholic acid, an endogenous metabolite, is a glycine-conjugated secondary bile acid and can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .
|
-
-
- HY-W750488
-
|
|
|
Glycolithocholic acid-d5 (Lithocholylglycine-d5) is the deuterium labeled Glycolithocholic acid (HY-116374). Glycolithocholic acid (Lithocholylglycine), an endogenous metabolite, is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .
|
-
-
- HY-W701772
-
|
|
|
2-Oleoylglycerol-d5 (2-OG-d5) is the deuterium labeled 2-Oleoylglycerol (HY-W011121). 2-Oleoylglycerol (2-OG) is a lipid found in the diet. It is a GPR119 agonist, with an EC50 value of 2.5 μM in activating hGPR119 in transiently transfected COS-7 cells. 2-Oleoylglycerol enhances the inflammatory response of macrophages and promotes fibrosis by activating the GPR119/TAK1/NF-κB/TGF-β1 signaling pathway. It also stimulates glucagon-like peptide 1 (GLP-1) secretion in vivo. 2-Oleoylglycerol is expected to be used in the research of non-alcoholic steatohepatitis (NASH) .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
